For personal use only

2026
Notice of
Annual General Meeting

9:00AM AEDT

Monday, 30 November 2026

CURVEBEAM AI LIMITED

ABN 32 140 706 618

Notice of Annual General Meeting

Notice is hereby given that the Annual General Meeting (**AGM or Meeting**) of Shareholders of CurveBeam AI Limited (**Company** or **CurveBeam AI**) will be held as a virtual-only meeting on Monday, 30 November 2026 commencing at 9:00am AEDT.

Details on how to participate in the AGM and voting procedures are set out below in the sections of this Notice titled "*Important information*" and "*Voting procedures*".

The Explanatory Memorandum provides additional information on matters to be considered at the Meeting.

Items of business

Item 1: Financial statements and reports

To receive and consider the Financial Report, the Directors' Report and the Auditor's Report for the Company for the financial year ended 30 June 2026.

All Shareholders can view the Annual Report, which contains the Financial Report, Directors' Report and Auditor's Report at the Company's investor website:

https://investors.curvebeamai.com/annual-reports/ or via the Company's announcement platform on ASX under the code "CVB".

Item 2: Remuneration Report

To consider and, if thought fit, pass the following as a **non-binding ordinary resolution** of the Company:

"*That the Remuneration Report for the year ended 30 June 2026 be adopted*."

Item 3: Election and re-election of Directors

Item 3.1: Re-election of Mr Robert Lilley as a Director

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That Mr Robert Lilley be re-elected as a Director of the Company."

Item 3.2: Election of Mr Patrick Fisher as a Director

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That Mr Patrick Fisher be elected as a Director of the Company."

Item 3.3: Election of Dr Yu Peng as a Director

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That Dr Yu Peng be elected as a Director of the Company."

Item 3.4: Election of Mr Daniel Pryor as a Director

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That Mr Daniel Pryor be elected as a Director of the Company."

For personal use only

Item 4: Ratification of prior issues of securities

Item 4.1: Ratification of prior issue of Shares (Listing Rule 7.1)

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the Company ratifies and approves the prior issue of 97,414,058 Shares under ASX Listing Rule 7.1, on the terms and conditions set out in the Explanatory Memorandum."

Item 4.2: Ratification of prior issue of Shares (Listing Rule 7.1A)

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the Company ratifies and approves the prior issue of 33,675,039 Shares under ASX Listing Rule 7.1A, on the terms and conditions set out in the Explanatory Memorandum."

Item 4.3: Ratification of prior issue of Advisory Fee Shares and Broker Options (Listing Rule 7.1)

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the Company ratifies and approves the prior issue of 1,111,111 Advisory Fee Shares and 5,000,000 Broker Options under ASX Listing Rule 7.1, on the terms and conditions set out in the Explanatory Memorandum."

Item 5: Renewal of the Company's Omnibus Incentive Plan

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

*"That, for the purposes of ASX Listing Rule 7.2 (exception 13(b)), sections 200B and 200E of the Corporations Act 2001 (Cth), the rules of the Company's Omnibus Incentive Plan (**Incentive Plan**) and for all other purposes, approval is hereby given for the renewal of the Incentive Plan and the granting of up to a maximum of 86,712,591 securities under the Incentive Plan on the terms and conditions which are described in the Explanatory Memorandum, during the three years following the date of this AGM."*

Item 6: Non-executive Director Fees

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 10.17, rule 8.5(a) of the Constitution and for all other purposes, the maximum total aggregate remuneration payable to Non-executive Directors in any financial year be increased by $200,000, from $450,000 to $650,000, on the terms set out in the Explanatory Memorandum."

Item 7: Issues of Shares to Directors

Item 7.1: Issue of Shares to Mr Robert Lilley

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 593,662 Shares to Mr Robert Lilley (or his nominee) as the equity-based component of

For personal use only

his remuneration as a Non-executive Director for the financial year ended 30 June 2026, on the terms set out in the Explanatory Memorandum."

Item 7.2: Issue of Shares to Mr Patrick Fisher

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 400,069 Shares to Mr Patrick Fisher (or his nominee) as the equity-based component of his remuneration as a Non-executive Director for the financial year ended 30 June 2026, on the terms set out in the Explanatory Memorandum."

Item 7.3: Issue of Shares to Dr Yu Peng

To consider and, if thought fit, pass the following as an **ordinary resolution** of the Company:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 548,544 Shares to Dr Yu Peng (or his nominee) in satisfaction of his short-term incentive for the financial year ended 30 June 2026, on the terms set out in the Explanatory Memorandum."

Item 8: Approval of additional 10% placement capacity to issue equity securities under ASX Listing Rule 7.1A

To consider and, if thought fit, pass the following as a **special resolution** of the Company:

"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given to the Company having the additional capacity to issue Equity Securities under Listing Rule 7.1A on the terms and conditions as detailed in the Explanatory Memorandum."

For personal use only

Voting Exclusions

Items 2 (Remuneration Report), 5 (Renewal of the Company's Omnibus Incentive Plan), 6 (Non-executive Director Fees) and 7 (Issues of Shares to Directors)

A vote on Item 2 must not be cast (in any capacity) by or on behalf of:

(a) any member or a former member of the KMP whose remuneration details are disclosed in the Company's 2026 Remuneration Report, or

(b) a Closely Related Party of such a KMP.

In addition, a vote must not be cast on Item 2, Item 5, Item 6 or Items 7.1 to 7.3 (inclusive) by a member of the KMP, or a Closely Related Party of a KMP, acting as proxy for a person entitled to vote.

However, such a person described above may cast a vote on Item 2, Item 5, Item 6 or Items 7.1 to 7.3 (inclusive) if:

(a) the person does so as proxy for a person entitled to vote in accordance with a direction on the Proxy Form; or

(b) the person is the Chair of the Meeting acting as proxy for a person entitled to vote on the relevant Item because the Company's proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the Item is connected directly or indirectly with the remuneration of a member of the Company's KMP.

Item 4.1 – Ratification of prior issue of Shares (Listing Rule 7.1)

The Company will disregard any votes cast in favour of the resolution at Item 4.1 by or on behalf of any persons who participated in the issue of the LR 7.1 Shares or an associate of those persons. However, the Company need not disregard a vote cast in favour of the resolution in Item 4.1 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with a direction given to the chair to vote on the relevant Item as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

  (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the relevant Item; and

  (ii) the holder votes on the relevant Item in accordance with directions given by the beneficiary to the holder to vote in that way.

Item 4.2 – Ratification of prior issue of Shares (Listing Rule 7.1A)

The Company will disregard any votes cast in favour of the resolution at Item 4.2 by or on behalf of any persons who participated in the issue of the LR 7.1A SPP Shares or an associate of those persons. However, the Company need not disregard a vote cast in favour of the resolution in Item 4.2 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with a direction given to the chair to vote on the relevant Item as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

  (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the relevant Item; and

  (ii) the holder votes on the relevant Item in accordance with directions given by the beneficiary to the holder to vote in that way.

For personal use only

Item 4.3 – Ratification of prior issue of Advisory Fee Shares and Broker Options

The Company will disregard any votes cast in favour of the resolution at Item 4.3 by or on behalf of Spark Plus, the Broker, any person who was issued Broker Options or an associate of those persons. However, the Company need not disregard a vote cast in favour of the resolution in Item 4.3 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with a direction given to the chair to vote on the relevant Item as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the relevant Item; and

(ii) the holder votes on the relevant Item in accordance with directions given by the beneficiary to the holder to vote in that way.

Item 5 – Renewal of the Company's Omnibus Incentive Plan

The Company will disregard any votes cast in favour of Item 5 by or on behalf of a person who is eligible to participate in the Incentive Plan or any of their associates. However, the Company need not disregard a vote cast in favour of Item 5 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with a direction given to the chair to vote on the relevant Item as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the relevant Item; and

(ii) the holder votes on the relevant Item in accordance with directions given by the beneficiary to the holder to vote in that way.

In addition, no KMP of the Company or a Closely Related Party of such a KMP may vote as a proxy on Item 5 unless the person votes as a proxy appointed by writing that specifies how the person is to vote on Item 5. This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as proxy for a person entitled to vote on Item 5 because the proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the resolution is connected directly or indirectly with the remuneration of KMP of the Company.

In addition, in accordance with section 200E(2A) of the Corporations Act, a vote on Item 5 must not be cast (in any capacity) by or on behalf of a participant in the Incentive Plan (other than a Non-executive Director) who holds, or has held, a managerial or executive office in the Company or a related body corporate and who may receive a benefit as a result of the approval sought under Item 5, or an associate of such a person. However, in accordance with section 200E(2B) of the Corporations Act, a vote may be cast by a person as a proxy appointed by writing that specifies how the proxy is to vote on Item 5, provided the vote is not cast on behalf of such a person or an associate of such a person.

Item 6 – Non-executive Director Fees

The Company will disregard any votes cast in favour of Item 6 by or on behalf of a Director or any of their associates. However, the Company need not disregard a vote cast in favour of Item 6 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant Item, in accordance with a direction given to the chair to vote on the relevant Item as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

For personal use only

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the relevant Item; and

(ii) the holder votes on the relevant Item in accordance with directions given by the beneficiary to the holder to vote in that way.

In addition, no KMP of the Company or a Closely Related Party of such a KMP may vote as a proxy on Item 6 unless the person votes as a proxy appointed by writing that specifies how the person is to vote on Item 6. This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as proxy for a person entitled to vote on Item 6 because the proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the resolution is connected directly or indirectly with the remuneration of KMP of the Company.

Item 7 – Issues of Shares to Directors

The Company will disregard any votes cast in favour of:

(a) the resolution in Item 7.1 by or on behalf of Mr Lilley and any other person who will obtain a material benefit as a result of the issue of the Director Shares to him (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their associates;

(b) the resolution in Item 7.2 by or on behalf of Mr Fisher and any other person who will obtain a material benefit as a result of the issue of the Director Shares to him (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their associates; and

(c) the resolution in Item 7.3 by or on behalf of Dr Peng and any other person who will obtain a material benefit as a result of the issue of the Director Shares to him (except a benefit solely by reason of being a holder of ordinary securities in the Company), or any of their associates.

However, the Company need not disregard a vote cast in favour of a resolution in Item 7 if it is cast by:

(a) a person as proxy or attorney for a person who is entitled to vote on the relevant resolution, in accordance with the directions given to the proxy or attorney; or

(b) the person chairing the meeting as proxy or attorney for a person who is entitled to vote on the relevant resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and

(ii) the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

In addition, no KMP of the Company or a Closely Related Party of such a KMP may vote as a proxy on a resolution in Item 7 unless the person votes as a proxy appointed by writing that specifies how the person is to vote on the resolution. This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as proxy for a person entitled to vote on a resolution in Item 7 because the proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the resolution is connected directly or indirectly with the remuneration of KMP of the Company.

Item 8 - Additional 10% placement capacity

At the date of this Notice of Meeting, the Company is not proposing to make an issue of equity securities under Listing Rule 7.1A.2. However, if at the time the approval is sought the Company does propose to make an issue of equity securities under Listing Rule 7.1A.2, the Company will disregard any votes cast in favour of Item 8 by or on behalf of a person who is expected to participate in, or who will obtain a material benefit as a result of the proposed issue of securities, except a benefit solely by reason of being a holder of ordinary securities, and any associates of the aforementioned persons.

However, this does not apply to a vote cast in favour of this resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on Item 8, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way; or

(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on Item 8, in accordance with a direction given to the Chair to vote on the resolution as the Chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

For personal use only

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on Item 8; and

(ii) the holder votes on Item 8 in accordance with directions given by the beneficiary to the holder to vote in that way.

BY ORDER OF THE BOARD



Phillip S Auckland

Chief Financial Officer & Company Secretary

29 October 2026

For personal use only

Important information

The Annual General Meeting of CurveBeam AI Limited will be held on **Monday, 30 November 2026 commencing at 9:00am AEDT**.

Virtual only meeting

The AGM will be held virtually. No physical meeting will be held. This means Shareholders will be able to attend and participate in the Meeting via an online virtual platform, which will include a live webcast and will enable Shareholders to watch and participate in the Meeting without being physically present.

Amongst other functions, the virtual platform will allow Shareholders to watch the Meeting, ask questions in relation to the business of the Meeting (at times specified by the Chair) and vote in real time. In addition, the Company will answer questions submitted by Shareholders in advance of the Meeting in accordance with the guidelines provided below under the heading "Submitting questions".

Shareholders must use the online platform to attend and participate in the Meeting. Shareholders will not be able to attend the Meeting in person. Accordingly, the Company strongly encourages all Shareholders who wish to vote to do so by:

- participating in the virtual Meeting and casting a vote online (see below); or
- appointing the Chair as their proxy by completing and returning the Proxy Form (and where desired, directing the Chair how to vote on each Resolution).

How to participate in the AGM

Before the AGM

AGM Notice of Meeting

Access online at the Company's investor website: https://investors.curvebeamai.com/ or at the Company's share registry's voting website www.investorvote.com.au

Request a hard copy of the Notice of Meeting by phone +61 3 9415 4000.

Vote or appoint a proxy

Return the hard copy Proxy Form or vote online at www.investorvote.com.au

To be valid, your proxy appointment must be received by **9:00am AEDT on Saturday, 28 November 2026.**

See the section entitled "Voting procedures" below for more details.

Ask a question online

Submit questions online at www.investorvote.com.au by **9:00am AEDT on Wednesday, 25 November 2026**.

See the section entitled "Submitting questions" below for more details.

At the AGM

Join online

- Online registration will be available one-hour prior to the Meeting.
- To register for the Meeting, please use the following link: https://meetnow.global/MRKX2U6
- To join the meeting online, you will need the latest versions of Chrome, Safari, Edge or Firefox. Please ensure that your browser is compatible.
- Click on 'Join Meeting Now'

Vote online

Only Shareholders, proxyholders, body corporate representatives or attorneys can vote.

- When the Chair declares the poll open, select the 'Vote' icon and the voting options will appear on your screen.
- To vote, select your voting direction. A tick will appear to confirm receipt of your vote.
- To change your vote, select 'Click here to change your vote' and

Ask a question online

Only Shareholders, proxyholders, body corporate representatives or attorneys can ask questions.

- Click on the 'Q & A' icon and select the Resolution your question relates to.
- Type your question into the chat box at the bottom of the screen and press 'Send'.
- The Chair will endeavour to address as many questions as

For personal use only

- If you are a Shareholder, enter your SRN/HIN (located on the top of your Proxy Form) and postcode.
- Enter your postcode registered to your holding if you are an Australian Shareholder. If you are an overseas Shareholder select the country of your registered holding from the drop down list.
- Accept the Terms and Conditions and click 'Continue'.
- If you are a proxy or other authorised representative, you will need to contact Computershare prior to the Meeting day on +61 3 9415 4024 to obtain your login details.

press a different option to override.

possible during the course of the meeting.

See the section entitled "Submitting questions" below for more details.

Submitting questions

Only Shareholders, proxyholders, body corporate representatives or attorneys can ask questions.

Before the AGM

Shareholders can submit questions in advance of the Meeting via the Share Registry website at www.investorvote.com.au.

Please submit any questions by **9:00am AEDT on Wednesday, 25 November 2026**.

Questions will be collated and the Chair and/or CEO will seek to address as many of the more frequently raised topics as possible during the Meeting. Please note that individual responses will not be sent to Shareholders.

At the AGM

Shareholders will be able to submit or ask questions or comments at any time during the meeting. To do so:

- Click on the 'Q & A' icon and select the Resolution your question relates to.
- Type your question into the chat box at the bottom of the screen and press 'Send'.

To ask a verbal question, follow the instructions on the virtual meeting platform.

We encourage you to ask your questions as early as possible in the Meeting.

The Chair will endeavour to address as many questions as possible during the course of the Meeting, however there may not be sufficient time available to address all of the questions raised.

Conduct of the Meeting

The Company is committed to ensuring that its Shareholder meetings are conducted in a manner which provides Shareholders who participate in the Meeting with the opportunity to participate in the business of the Meeting in an orderly fashion and to ask questions about and comment on matters relevant to the business of the meeting or about CurveBeam AI generally.

The Chair of the Meeting will exercise his powers as the Chair to ensure that the Meeting is conducted in an orderly and timely fashion, in the interests of Shareholders who are participating in the Meeting.

Enclosures

If you have elected to receive communications from the Company by mail, enclosed with the Notice are the following documents:

- Proxy Form to be completed if you wish to vote prior to the Meeting and do not wish to use the online voting facility. Shareholders are encouraged to use the online voting facility described above to ensure the timely and cost-effective receipt of your proxy; and
- A reply-paid envelope for you to return the Proxy Form if you do not use the online facility.

For personal use only

Further information

Further information about how to log in to the Computershare Meeting Platform and how to participate online at the Annual General Meeting is available in the Online Meeting Guide, which you can access at www.computershare.com.au/virtualmeetingguide.

You may elect to receive meeting related documents, or request a particular one, in electronic or physical form and you may elect not to receive annual reports. To do so, contact Computershare.

Glossary

The Glossary at the end of this Notice contains the meanings of key terms that are capitalised in this Notice and which are not otherwise defined in the body of the Notice.

For personal use only

Voting procedures

All resolutions will be by poll

In accordance with section 250JA of the Corporations Act and rule 7.12(f) of the Constitution, each of the resolutions proposed at the Meeting will be decided on a poll.

Entitlement to vote

The Directors have determined pursuant to regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders of the Company as at **7:00pm (AEDT) on Saturday, 28 November 2026** (**Entitlement Time**).

This means that if you are not the registered holder of a Share in the Company at the Entitlement Time, you will not be entitled to vote at the Meeting.

How to vote – before the Meeting

Appointment of Proxy

Shareholders who are entitled to vote at the AGM can appoint a proxy to participate and vote on their behalf.

Shareholders can appoint a proxy online at www.investorvote.com.au. Shareholders who receive their AGM pack via email will receive a personalised link to InvestorVote in order to appoint a proxy.

Shareholders who have elected to receive their AGM pack via mail will be sent a personalised hard copy Proxy Form via post.

A Shareholder who is entitled to vote at the Meeting is entitled to appoint not more than two proxies to vote in place of the Shareholder. If the Shareholder appoints two proxies, the Shareholder may specify the proportion or number of votes each proxy is entitled to exercise. If no proportion or number of votes is specified, each proxy may exercise half of the Shareholder's votes. If the specified proportion or number of votes exceeds that which the Shareholder is entitled to, each proxy may exercise half of the Shareholder's votes. Any fractions of votes brought about by the apportionment of votes to a proxy will be disregarded.

A proxy need not be a Shareholder of the Company and can be either an individual or a body corporate. If you wish to appoint a body corporate as your proxy, that body corporate will need to ensure that it:

- appoints an individual as a corporate representative to exercise its powers at the meeting, in accordance with section 250D of the Corporations Act; and
- provides satisfactory evidence of the appointment of its corporate representative in advance of the meeting.

The form of appointment, including any authority under which it is signed (e.g., a power of attorney), must be received by the Share Registry by no later than **9:00am (AEDT) on Saturday, 28 November 2026** (which is 48 hours prior to the commencement of the Meeting), unless it has previously been given to the Company. An appointment of corporate representative form can be obtained from Computershare by calling 1800 158 360 (within Australia) or +61 3 9415 4208 (outside Australia) or downloaded from https://www-au.computershare.com/investor/

Subject to the specific proxy voting rules applying to Items 2, 5, 6 and 7 (see the Explanatory Memorandum):

- if a Shareholder has not directed their proxy how to vote, the proxy may vote as the proxy determines; and
- if a Shareholder appoints the Chair of the Meeting as proxy and does not direct the Chair how to vote on an item of business, the Chair will vote in accordance with his voting intention as stated in this Notice of Meeting.

Submitting your Proxy Form

To be valid, a Proxy Form must be received by the Company in the manner set out in this Notice.

The Chair's decision on the validity of a vote cast by a proxy or vote cast directly at the Meeting is conclusive and the Company reserves the right to declare invalid any Proxy Form not received in this manner.

Proxy forms may be submitted in one of the following ways:

For personal use only

Online:	Through your personalised link or by visiting www.investorvote.com.au and following the prompts.
By post:	Computershare Investor Services Pty Limited, GPO Box 242, Melbourne, VIC 3001. Please allow sufficient time so that it reaches Computershare by the Proxy Deadline.
By fax:	1800 783 447 (within Australia), +61 3 9473 2555 (outside Australia).
Custodian voting:	For Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions.

Proxy Deadline

For your proxy vote prior to the Meeting to be effective, your Proxy Form (together with the relevant original power of attorney or a certified copy if the proxy is signed by an attorney) must be received by the Company's Share Registry, Computershare, no later than **9:00am AEDT on Saturday, 28 November 2026**. Proxy Forms received after this time will not be valid; however, you will still be able to vote during the Meeting by using the online platform.

How to vote – during the Meeting

During the Meeting Shareholders can vote directly using the online platform. See "How to participate in the AGM" in the Important information section of this Notice for details on how to do so.

Proxy voting by the Chair

For Items 2, 5, 6 and 7 where the Chair is appointed as a Shareholder's proxy and that Shareholder has not specified the way in which the Chair is to vote, the Shareholder is expressly authorising the Chair to vote in accordance with the Chair's voting intentions for these items of business, even though Items 2, 5, 6 and 7 are connected directly or indirectly with the remuneration of Key Management Personnel, which includes the Chair.

The Chair intends to vote all undirected proxies in favour of all the resolutions in the Notice of Meeting, including Items 2, 5, 6 and 7.

For personal use only

Explanatory Memorandum

This Explanatory Memorandum has been prepared for the information of Shareholders of the Company in relation to the business to be conducted at the Company's annual general meeting to be held at **9:00am AEDT on Monday, 30 November 2026**.

The purpose of this Explanatory Memorandum is to provide Shareholders with information that is reasonably required by Shareholders to decide how to vote on the resolutions.

Subject to the abstentions noted below in respect of each resolution, the Board recommends that Shareholders vote in favour of all resolutions. The Chair of the Meeting intends to vote all available undirected proxies in favour of each resolution.

All resolutions, other than the resolution in Item 8, are ordinary resolutions, which require a simple majority of votes cast by Shareholders entitled to vote on the resolution to be in favour for the resolution to be approved. The resolution in Item 8 is a special resolution, which requires at least 75% of the votes cast by Shareholders entitled to vote on the resolution to be in favour for the resolution to be approved.

Item 1 – Financial statements and reports

As required by section 317 of the Corporations Act, the Financial Report, Directors' Report and Auditor's Report of the Company will be presented at the Meeting. The Financial Report contains the financial statements of the Company and its controlled entities for the financial year ended 30 June 2026.

There is no requirement for a formal resolution on this Item.

The Chair of the Meeting will allow a reasonable opportunity at the Meeting for Shareholders to ask questions about, or make comments on, the management of the Company, and to ask questions about the Financial Report. Shareholders will also be given a reasonable opportunity at the Meeting to ask the Company's auditor, BDO Audit Pty Ltd (**BDO**)**,** questions about the Auditor's Report, the conduct of its audit of the Financial Report, the preparation and content of the Auditor's Report, the accounting policies adopted by the Company in its preparation of the financial statements and the independence of BDO in relation to the conduct of the audit.

Shareholders may submit written questions to the Company in relation to the above matters and the way to do this is outlined earlier in this Notice. However, in accordance with section 250PA of the Corporations Act, written questions to BDO about the content of the Auditor's Report or the conduct of the audit must be received by the Company no later than Monday, 23 November 2026.

Item 2 – Remuneration Report

The Company has prepared a Remuneration Report for consideration and adoption by Shareholders. The Remuneration Report on pages 21-41 of the Company's Annual Report for the year ended 30 June 2026 sets out the remuneration policies of the Company and reports on the remuneration arrangements and outcomes for KMP, including the directors and executives of the Company. The 2026 Annual Report is available at https://investors.curvebeamai.com/annual-reports/.

As provided by section 250R(3) of the Corporations Act, the resolution on this item of business is advisory only and does not bind the Board or the Company. The Board will consider the outcome of the vote and comments from Shareholders when reviewing the Company's remuneration policies.

Remuneration link with company performance and strategy

The Company's remuneration framework is aimed at rewarding executives and employees for the achievement of growth in the business, successful implementation and achievement of corporate milestones, and the creation of Shareholder value in the short, medium and long-term. The Company's remuneration framework and pay for performance philosophy is intended to attract, motivate and retain talent so the Company may deliver on its growth strategy and utilise remuneration mechanisms that can also further align the cash strategy of the business.

The Board is committed to good governance in remuneration and to ensuring that the Group's policies and practices are fair, competitive and responsible. As noted in the Remuneration Report, the Remuneration Committee and the Board have endeavoured to oversee the execution of remuneration policy prudently through challenging times, with Shareholders' interests firmly in mind.

Board recommendation
Noting that each Director has a personal interest in their own remuneration, the Directors recommend that Shareholders vote FOR the resolution in Item 2.

For personal use only

Item 3 – Election and re-election of Directors

In accordance with rule 8.1(e) of the Company's Constitution and Listing Rule 14.4, Mr Robert Lilley will retire at the Annual General Meeting and being eligible, will offer himself for re-election at the Meeting. Prior to submitting himself for re-election, Mr Lilley has confirmed that he will continue to have sufficient time to fulfil his duties as a Director of the Company. Having had regard to the ASX Principles, the Board (with Mr Lilley not participating) considers Mr Lilley to be an independent director.

Mr Patrick Fisher has been appointed as an addition to the Board since the last Annual General Meeting of the Company and offers himself for election in accordance with rule 8.1(d) of the Company's Constitution and Listing Rule 14.4. Prior to submitting himself for election, Mr Fisher has confirmed that he will have sufficient time to fulfil his duties as a Director of the Company. Having had regard to the ASX Principles, the Board (with Mr Fisher not participating) considers Mr Fisher to be an independent director.

Dr Yu Peng has been appointed as an addition to the Board since the last Annual General Meeting of the Company and offers himself for election in accordance with rule 8.1(d) of the Company's Constitution and Listing Rule 14.4. Prior to submitting himself for election, Dr Peng has confirmed that he will have sufficient time to fulfil his duties as a Director of the Company. Having had regard to the ASX Principles, the Board (with Dr Peng not participating) considers that Dr Yu Peng is not an independent director because he is an executive director of the Company.

Mr Daniel Pryor has been appointed as an addition to the Board since the last Annual General Meeting of the Company and offers himself for election in accordance with rule 8.1(d) of the Company's Constitution and Listing Rule 14.4. Prior to submitting himself for election, Mr Pryor has confirmed that he will have sufficient time to fulfil his duties as a Director of the Company. Having had regard to the ASX Principles, the Board (with Mr Pryor not participating) considers Mr Pryor to be an independent director.

A summary of each of their respective qualifications and expertise is set out below:

Item 3.1 – Re-election of Mr Robert Lilley as a Director

Mr Robert Lilley was appointed to the Board of the Company on 16 April 2021 and commenced as Chair on 26 April 2021. Mr Lilley has over 35 years' experience in the medical device and diagnostics industries. Mr Lilley previously served as senior vice president of global sales and marketing for Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN). Mr Lilley is currently the Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company. Mr Lilley holds a BA from Yale University, US.

Board recommendation
The Board (with Mr Lilley abstaining) supports the re-election of Mr Lilley and recommends that Shareholders vote FOR Mr Lilley's re-election as a Director of the Company.

Item 3.2 – Election of Mr Patrick Fisher as a Director

Mr Patrick Fisher was appointed to the Board of the Company on 19 March 2026 as a Non-executive Director. Mr Fisher is US-based and a highly experienced global orthopaedic industry executive with more than two decades of leadership experience across global medical device organisations. Mr Fisher has a Bachelor of Arts in International Studies from Rhodes College and a Master of Business Administration in International Business from the University of Memphis.

He currently serves as President of Global Biologics and Limb Reconstruction at Orthofix and has previously held senior leadership roles at Stryker and Wright Medical Group, where he was involved across knee, hip, and foot & ankle segments. Mr Fisher brings deep expertise in global orthopaedic markets, commercial strategy, capital equipment deployment, and surgeon engagement. Mr Fisher also serves on the University of Tennessee Research Advisory Board, and the Mission 3A Healthcare Advisory Board.

Board recommendation
The Board (with Mr Fisher abstaining) supports the election of Mr Fisher and recommends that Shareholders vote FOR Mr Fisher's election as a Director of the Company.

Item 3.3 – Election of Dr Yu Peng as a Director

Dr Yu Peng was appointed to the Board of the Company on 3 September 2026 as an Executive Director. Dr Peng joined CurveBeam AI in 2012 and has served as Chief Technology Officer (AI) since 2021. Dr Peng has over 15 years' experience in computer vision and machine learning and oversees technical strategy and development at CurveBeam AI, including medical image analysis, machine learning and cloud computing. Dr Peng received his PhD in Computer Vision and Machine Learning from the University of Newcastle, Australia. Dr Peng also held a Visiting Professor position (honorary) in Artificial Intelligence (AI) at the University of Technology, Sydney, Australia from 2019 to 2022.

For personal use only

Dr Peng also brings a deep understanding of the Chinese healthcare and medical technology markets, including the commercial, cultural and relationship dynamics that are important to successfully developing the Company's strategic relationship with Wego Orthopaedics. In addition, he brings to the boardroom the knowledge to ensure that the Board is well informed on the Company's technologies and their development and commercialisation pathways.

Board recommendation
The Board (with Dr Peng abstaining) supports the election of Dr Peng and recommends that Shareholders vote FOR Dr Peng's election as a Director of the Company.

Item 3.4 – Election of Mr Daniel Pryor as a Director

Mr Daniel Pryor was appointed to the Board of the Company on 25 October 2026 as a Non-executive Director and Chair of the Audit & Risk Committee. Mr Pryor has more than 30 years' experience across the industrial and medical device sectors, including senior executive roles at Enovis Corporation (orthopaedics) and Danaher Corporation, as well as a senior private equity investment role at The Carlyle Group. As Executive Vice President at Enovis, he helped lead its transformation into a global medical technology platform through more than 50 acquisitions and divestitures representing over US$14 billion in enterprise value.

Mr Pryor's experience spans strategic transformation, mergers and acquisitions, divestitures and corporate development, providing a valuable combination of operational leadership and investment expertise. He holds a Bachelor of Arts in Economics from Williams College and an MBA from Harvard Business School. Mr Pryor is based in Washington DC in the United States, within driving distance of the Company's US operations headquarters.

Board recommendation
The Board (with Mr Pryor abstaining) supports the election of Mr Pryor and recommends that Shareholders vote FOR Mr Pryor's election as a Director of the Company.

Item 4: Ratification of prior issues of Securities

Item 4.1 – Ratification of prior issue of Shares (Listing Rule 7.1)

Background

On 8 July 2026, the Company announced a placement of approximately 250,000,000 Shares at $0.020 together with a share purchase plan under which eligible Shareholders could subscribe for Shares at an issue price of $0.018 per Share (**SPP**). The SPP was made under a prospectus dated 4 August 2026 (**Prospectus**), which also provided for any shortfall under the SPP to be offered to other investors (**Shortfall Offer**). The Shares issued under the placement announced on 8 July 2026 were approved by Shareholders at the general meeting held on 21 August 2026 and is not the subject of this Item.

The SPP closed on 28 August 2026. Under a mandate dated 31 August 2026, the Company engaged SP Corporate Advisory Pty Ltd (**Broker**) and Spark Plus Pte Ltd (**Spark Plus**) to place the Shortfall Offer. The Shortfall Offer was ultimately oversubscribed and the Company accepted a further $359,603.75 of demand by way of a placement at $0.018 per Share (**Overflow Placement**). On 18 September 2026, the Company announced that it had raised approximately $1.75 million under the Shortfall Offer and the Overflow Placement.

Funds raised under the SPP, the Shortfall Offer and the Overflow Placement (after capital raising costs) have been or will be used for sales and marketing expenses (including China market launch preparation for the HiRise™), R&D costs (including product enhancements for the HiRise™), supply chain costs and general working capital purposes (including the expenses of the SPP and the Shortfall Offer).

The resolution at Item 4.1 seeks Shareholder ratification pursuant to Listing Rule 7.4 for the issue of 97,414,058 Shares issued under Listing Rule 7.1, comprising 77,244,236 Shares issued under the Shortfall Offer, 191,836 Shares issued under the SPP on 25 September 2026 and 19,977,986 Shares issued under the Overflow Placement (together, the **LR 7.1 Shares**).

The resolution at Item 4.2 seeks Shareholder ratification pursuant to Listing Rule 7.4 for the issue of 33,675,039 Shares issued under the SPP under Listing Rule 7.1A (**LR 7.1A SPP Shares**).

The resolution at Item 4.3 seeks Shareholder ratification of the issue of securities to the Company's advisers in connection with the Shortfall Offer and the Overflow Placement.

Why is shareholder approval being sought?

Listing Rule 7.1 provides that an entity must not, subject to specified exceptions, issue or agree to issue more Equity Securities during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period.

For personal use only

For personal use only

However, ASX Listing Rule 7.4 provides that where a listed company in general meeting subsequently approves a prior issue of securities and that prior issue did not breach ASX Listing Rule 7.1, those securities will be treated as having been made with shareholder approval for the purpose of ASX Listing Rule 7.1.

The Company is seeking Shareholder approval for the issue of the LR 7.1 Shares for the purposes of ASX Listing Rule 7.4 to enable the Company to retain the flexibility to issue new equity securities following the Meeting and up to the 15% limit in ASX Listing Rule 7.1, without the need to seek Shareholder approval.

If the resolution at Item 4.1 is passed by Shareholders, the issue of the 97,414,058 LR 7.1 Shares will be excluded from the calculations of the Company's 15% limit under Listing Rule 7.1 and the Company will retain the flexibility to issue new equity securities following the Meeting and up to the 15% limit in ASX Listing Rule 7.1, without the need to seek further Shareholder approval.

If the resolution at Item 4.1 is not passed by Shareholders, the 97,414,058 LR 7.1 Shares will be included in calculating the Company's 15% limit under ASX Listing Rule 7.1, effectively decreasing the number of Equity Securities the Company can issue without Shareholder approval over the 12-month period following the issue date of the LR 7.1 Shares.

Specific Information required by ASX Listing Rule 7.5

The following further information in relation to the LR 7.1 Shares the subject of the resolution in Item 4.1 is provided to Shareholders for the purposes of Listing Rule 7.5:

Names of the persons to whom the Company issued the LR 7.1 Shares or the basis upon which those persons were identified or selected	The Shares issued under the Shortfall Offer and the Overflow Placement were issued to Australian and international investors identified by the Broker and Spark Plus. The recipients were identified through a bookbuild process, which involved the Broker and Spark Plus seeking expressions of interest to participate in the Shortfall Offer from non-related parties of the Company. The 191,836 Shares issued under the SPP on 25 September 2026 were issued to eligible Shareholders on the SPP record date who applied under the SPP. The Company confirms that none of the recipients was a related party of the Company, a member of the Company's Key Management Personnel, a substantial holder of the Company, an adviser of the Company or an associate of any of these parties who was issued more than 1% of the issued capital of the Company.
The number and class of securities issued	97,414,058 fully paid ordinary shares ranking equally with all existing ordinary shares on issue, all of which were issued under the Company's Listing Rule 7.1 capacity.
Date of issue	Shortfall Offer: 67,638,887 Shares on 25 September 2026 and 9,605,349 Shares on 30 September 2026. Overflow Placement: 7,755,763 Shares on 30 September 2026 and 12,222,223 Shares on 9 October 2026. SPP: The 191,836 SPP Shares were issued on 25 September 2026.
Issue price or other consideration the Company has received for the issue of each LR 7.1 Share	The issue price was $0.018 for each LR 7.1 Share raising approximately $1.75 million in aggregate (before costs). The Company has not and will not receive any other consideration for the issue of the LR 7.1 Shares.
The purpose of issue	The LR 7.1 Shares were issued to raise funds for sales and marketing expenses (including China market launch preparation for the HiRise™), R&D costs, supply chain costs and general working capital purposes (including the expenses of the offer).
The material terms of the Agreement	The Shares issued under the Shortfall Offer and the SPP were issued on the terms of the Prospectus. The Shares issued under the Overflow Placement were issued under placement commitments on the same terms. Further details are contained in the Prospectus released to ASX on 4 August 2026 and the announcement released by the Company to ASX on 18 September 2026, which can be viewed on ASX's website at: https://announcements.asx.com.au/asxpdf/20260918/pdf/07477yqgc1hrzx.pdf

Board recommendation
The Board recommends that Shareholders vote FOR the resolution in Item 4.1.

Item 4.2 – Ratification of prior issue of Shares (Listing Rule 7.1A)

Background

The background to the SPP is set out under Item 4.1 above. On 4 September 2026, the Company issued 33,675,039 Shares under the SPP at an issue price of $0.018 per Share, raising approximately $606,151 (before costs). These Shares were issued in reliance on the Company's placement capacity under Listing Rule 7.1A.

Why is shareholder approval being sought?

The resolution at Item 4.2 seeks Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the 33,675,039 LR 7.1A SPP Shares issued under Listing Rule 7.1A.

Listing Rule 7.1A provides that in addition to issues permitted without prior Shareholder approval under ASX Listing Rule 7.1, an entity that is eligible and obtains shareholder approval under ASX Listing Rule 7.1A may issue or agree to issue, during the period the approval is valid, a number of Equity Securities which represents 10% of the number of fully paid ordinary securities on issue at the commencement of the relevant 12-month period as adjusted in accordance with the formula in ASX Listing Rule 7.1A.

Having obtained Shareholder approval at the Company's Annual General Meeting on 27 November 2025, the Company has an additional 10% placement capacity under Listing Rule 7.1A.

Issues of securities made under Listing Rule 7.1A can also, after they have been made, be ratified under Listing Rule 7.4. This has the effect of refreshing the Company's ability to issue Shares within the additional 10% limit and restoring the Company's ability to make placements within that limit without the need for Shareholder approval.

If the resolution in Item 4.2 is approved by Shareholders:

- the Company will retain the flexibility to issue Equity Securities within the additional 10% limit under ASX Listing Rule 7.1A (subject to the resolution in Item 8 being passed).
- the 33,675,039 LR 7.1A SPP Shares will be counted in variable "A" in the formula in ASX Listing Rule 7.1 and therefore increase the Company's ASX Listing Rule 7.1 15% capacity.

If the resolution in Item 4.2 is not passed by Shareholders, the 33,675,039 LR 7.1A SPP Shares will be included in calculating the Company's 10% limit under ASX Listing Rule 7.1A. In addition, the 33,675,039 LR 7.1A SPP Shares will not be counted in variable "A" in the formula in ASX Listing Rule 7.1 for the purposes of calculating the Company's ASX Listing Rule 7.1 15% capacity.

Specific Information required by ASX Listing Rule 7.5

The following further information in relation to the LR 7.1A SPP Shares the subject of the resolution in Item 4.2 is provided to Shareholders for the purposes of Listing Rule 7.5:

Names of the persons to whom the Company issued the LR 7.1A SPP Shares or the basis upon which those persons were identified or selected	The LR 7.1A SPP Shares were issued to eligible Shareholders (being Shareholders with a registered address in Australia, New Zealand, the United States (accredited investors only), Singapore, Hong Kong, Germany, France (qualified investors only) or the United Kingdom as at the SPP record date of 7:00pm (Australian Eastern Standard Time) on 7 July 2026) who applied for Shares under the SPP. The Company confirms that none of the recipients was a related party of the Company, a member of the Company's Key Management Personnel, a substantial holder of the Company, an adviser of the Company or an associate of any of these parties who was issued more than 1% of the issued capital of the Company.
The number and class of securities issued	33,675,039 fully paid ordinary shares ranking equally with all existing ordinary shares on issue, all of which were issued under the Company's Listing Rule 7.1A capacity.
Date of issue	4 September 2026.
Issue price or other consideration the Company has received for the issue of each LR 7.1A SPP Share	The issue price was $0.018 for each LR 7.1A SPP Share raising approximately $606,151 in aggregate (before costs). The Company has not and will not receive any other consideration for the issue of the LR 7.1A SPP Shares.
The purpose of issue	The LR 7.1A SPP Shares were issued to raise funds for sales and marketing expenses (including China market launch preparation for the HiRise™), R&D

For personal use only

	costs, supply chain costs and general working capital purposes (including the expenses of the offer).
The material terms of the Agreement	The LR 7.1A SPP Shares were issued on the terms of the Prospectus. Further details are contained in the Prospectus released to ASX on 4 August 2026, which can be viewed on the Company website at https://wcsecure.weblink.com.au/pdf/CVB/03117650.pdf

Board recommendation
The Board recommends that Shareholders vote FOR the resolution in Item 4.2.

Item 4.3 – Ratification of prior issue of Advisory Fee Shares and Broker Options (Listing Rule 7.1)

Background

As noted under Item 4.1, the Company engaged the Broker and Spark Plus to place the Shortfall Offer under a mandate dated 31 August 2026 (**Mandate**). In consideration for services provided in connection with the Shortfall Offer and the Overflow Placement, the Company issued 1,111,111 Shares to Spark Plus in satisfaction of a corporate advisory fee of $20,000 (**Advisory Fee Shares**) and 5,000,000 unquoted options, each exercisable at $0.04 and expiring on 30 September 2027 (**Broker Options**), to participating brokers selected by the Company following recommendations from Spark Plus.

The Advisory Fee Shares and the Broker Options were issued in reliance on the Company's placement capacity under Listing Rule 7.1.

The resolution at Item 4.3 seeks Shareholder ratification pursuant to Listing Rule 7.4 for the issue of the Advisory Fee Shares and the Broker Options.

Why is shareholder approval being sought?

Listing Rule 7.1 provides that an entity must not, subject to specified exceptions, issue or agree to issue more Equity Securities during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period.

However, ASX Listing Rule 7.4 provides that where a listed company in general meeting subsequently approves a prior issue of securities and that prior issue did not breach ASX Listing Rule 7.1, those securities will be treated as having been made with shareholder approval for the purpose of ASX Listing Rule 7.1.

The Company is seeking Shareholder approval for the issue of the Advisory Fee Shares and the Broker Options for the purposes of ASX Listing Rule 7.4 to enable the Company to retain the flexibility to issue new equity securities following the Meeting and up to the 15% limit in ASX Listing Rule 7.1, without the need to seek Shareholder approval.

If the resolution at Item 4.3 is passed by Shareholders, the issue of the Advisory Fee Shares and the Broker Options will be excluded from the calculations of the Company's 15% limit under Listing Rule 7.1 and the Company will retain the flexibility to issue new equity securities following the Meeting and up to the 15% limit in ASX Listing Rule 7.1, without the need to seek further Shareholder approval.

If the resolution at Item 4.3 is not passed by Shareholders, the Advisory Fee Shares and the Broker Options will be included in calculating the Company's 15% limit under ASX Listing Rule 7.1, effectively decreasing the number of Equity Securities the Company can issue without Shareholder approval over the 12-month period following their issue date.

Specific Information required by ASX Listing Rule 7.5

The following further information in relation to the Advisory Fee Shares and the Broker Options the subject of the resolution in Item 4.3 is provided to Shareholders for the purposes of Listing Rule 7.5:

Names of the persons to whom the Company issued the Advisory Fee Shares and the Broker Options or the basis upon which those persons were identified or selected	The Advisory Fee Shares were issued to Spark Plus. The Broker Options were issued to participating brokers selected by the Company following recommendations from Spark Plus. Spark Plus is an adviser to the Company. However, the Advisory Fee Shares represent less than 1% of the Company's issued capital. Each recipient of the Broker Options is an adviser to the Company. However, the Broker Options issued to each of them represent less than 1% of the Company's issued capital. None of the recipients of the Broker Options is a related party, member of the Company's Key Management Personnel or substantial holder of the Company, or an associate of any of them.

For personal use only

The number and class of securities issued	1,111,111 fully paid ordinary shares ranking equally with all existing ordinary shares on issue, and 5,000,000 unquoted options. Each Broker Option is exercisable at $0.04 on or before 30 September 2027 and, on exercise, entitles the holder to one fully paid ordinary share ranking equally with existing Shares. The Broker Options are not subject to vesting conditions. All were issued under the Company's Listing Rule 7.1 capacity.
Date of issue	The Advisory Fee Shares were issued on 30 September 2026 and the Broker Options were issued on 9 October 2026.
Issue price or other consideration the Company has received for the issue of each Advisory Fee Share and Broker Option	The Advisory Fee Shares were issued for nil cash consideration in satisfaction of a corporate advisory fee of $20,000 (equivalent to a deemed issue price of $0.018 per Share). The Broker Options were issued for nil cash consideration as part of the fees for broker services provided in connection with the Shortfall Offer and the Overflow Placement. No funds were raised from the issue, as the issue was for services provided. If all Broker Options are exercised, the Company will receive $200,000, which it intends to apply to general working capital.
The purpose of issue	The Advisory Fee Shares and the Broker Options were issued to remunerate Spark Plus and the participating brokers for services provided in connection with the Shortfall Offer and the Overflow Placement, allowing the Company to preserve its cash reserves.
The material terms of the Agreement	The Advisory Fee Shares and the Broker Options were issued under the Mandate. Under the Mandate, the Company agreed to pay a corporate advisory fee of $20,000 (settled by the issue of the Advisory Fee Shares), cash commissions of 5% of the first $500,000 raised, 6.5% of amounts raised between $500,000 and $1,000,000 and 8% of amounts raised above $1,000,000, and to issue the Broker Options for allocation to participating brokers. Further details are contained in the Appendix 3B released by the Company to ASX on 18 September 2026 and can be viewed on the Company website https://wcsecure.weblink.com.au/pdf/CVB/03136875.pdf

Board recommendation
The Board recommends that Shareholders vote FOR the resolution in Item 4.3.

Item 5 – Renewal of Omnibus Incentive Plan

Background

This Item seeks Shareholder approval for the renewal of the Company's Omnibus Incentive Plan (**Incentive Plan**) and for the issue of securities under the Incentive Plan in accordance with Listing Rule 7.2 (exception 13(b)).

The objective of the Incentive Plan is to attract, motivate and retain key directors, senior executives and other employees who may be invited to participate in the Incentive Plan from time to time. The Company considers that the continued operation of the Incentive Plan and the future issue of securities under the Incentive Plan will provide selected directors, executives and employees with the opportunity to participate in the future growth of the Company.

A summary of the key terms of the Incentive Plan is set out in Annexure A.

ASX Listing Rules

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that an ASX-listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

For personal use only

Under Listing Rule 7.2 (exception 13(b)), Shareholders may approve the issue of securities under an employee incentive scheme as an exception to Listing Rules 7.1 and 7.1A. If such approval is obtained, any securities granted under the Incentive Plan would not be counted towards the Company's capacity to issue securities under the applicable issue limit within three years of the date of the approval.

Relevantly, exception 13(b) of Listing Rule 7.2 is only available to the Company if:

(a) Shareholders have approved the issue of Equity Securities under the employee incentive scheme within three years of the date of any issue under that scheme; and

(b) the number of Equity Securities issued under an employee incentive scheme does not exceed the maximum number set out in an entity's notice of meeting.

Shareholders approved the Incentive Plan for the purposes of ASX Listing Rule 7.2 exception 13(b) at the Company's Annual General Meeting held on 27 November 2025, with a maximum of 23,500,000 Equity Securities. Since that approval, the Company's share price has declined significantly. As awards under the Incentive Plan are generally sized by reference to value, the existing maximum is unlikely to be sufficient for grants over the next three years. The Company therefore seeks a fresh approval for the Incentive Plan in accordance with ASX Listing Rule 7.2 exception 13(b) with a higher maximum, which, if approved, will enable securities issued under the Incentive Plan over the course of the next three years to be excluded from the Company's 15% limit for the purpose of ASX Listing Rule 7.1.

If the resolution at Item 5 is passed, the Company will be able to issue up to 86,712,591 Equity Securities under the Incentive Plan without further Shareholder approval and without those securities being included in the calculation of the Company's 15% placement capacity under Listing Rule 7.1 for a period of three years from the date the resolution in Item 5 is passed. The approval given at the Company's 2025 Annual General Meeting will then cease to apply, and any unused capacity under that approval will no longer be available.

If Shareholder approval to the resolution at Item 5 is not obtained, the approval given at the Company's 2025 Annual General Meeting will continue to apply until its 23,500,000 maximum is reached or it expires. Any Equity Securities issued under the Incentive Plan outside that approval would reduce the number of Equity Securities which the Company can issue without Shareholder approval under the limit imposed by Listing Rule 7.1 until such time as the Company obtains Shareholder approval under exception 13(b) of Listing Rule 7.2 for the Incentive Plan in the future. In that scenario, the Board may need to consider alternative remuneration arrangements which are consistent with the Company's remuneration principles, including providing an equivalent cash long term incentive, subject to the risk of forfeiture, performance conditions and performance period.

Subject to Shareholder approval, this approval would continue for three years, at which time it must be renewed, or it will expire. For the avoidance of doubt, under ASX Listing Rules 10.11 and 10.14, any specific issue of securities to a director (and/or his or her associates) or other relevant persons under an employee incentive scheme will need additional shareholder approval. The Company will seek such additional approval before issuing any securities under the Incentive Plan where required to do so.

The Board intends to make regular grants of securities under the Incentive Plan to selected directors, executives and employees. Offers will be made at the discretion of the Board. The terms of the securities granted under the Incentive Plan will be determined by the Board at grant and may therefore vary over time. In the Board's opinion, Item 5 will assist the Company in managing its capital requirements efficiently by ensuring that the Company's issue limit is not diminished by issues under the Incentive Plan and capacity is available for capital management initiatives and acquisitions, if necessary and appropriate.

Corporations Act

In respect of Item 5, Shareholders are also being asked to approve the ability for the Board to be able to exercise certain discretions under the Incentive Plan in relation to the treatment of unvested awards (performance rights, options and shares) that may be granted under the Incentive Plan.

Specific information required by Listing Rule 7.2 (exception 13(b))

As required by Listing Rule 7.2 (exception 13(b)), the following information is provided:

(a) a summary of the key terms of the Incentive Plan is set out in Annexure A;

(b) since the Incentive Plan was last approved by Shareholders on 27 November 2025, the Company has issued a total of 4,876,052 Shares under the Incentive Plan in reliance on that approval. In addition, the Company has issued 1,235,843 Shares on the conversion of Share Rights granted under the Incentive Plan before that approval. Those Shares were issued under Listing Rule 7.2 (exception 9) and do not count towards the maximum approved at the 2025 Annual General Meeting;

(c) the maximum number of Equity Securities proposed to be issued under the Incentive Plan following Shareholder approval is 86,712,591, which constitutes no more than approximately 10% of the total Shares on issue as at the

For personal use only

date of this Notice. The maximum number is not intended to be a prediction of the actual number of securities to be issued under the Incentive Plan, simply a ceiling for the purposes of Listing Rule 7.2 (exception 13(b)) and the rules of the Incentive Plan.

(d) in addition to the securities referred to in paragraph (b), the Company intends to issue up to 18,591,938 Equity Securities (details of which are provided below) under the Incentive Plan to eligible employees who are not Directors between the date of this Notice and the date of the Meeting, in reliance on the approval obtained at the Company's 2025 Annual General Meeting. Those securities will be issued within the maximum of 23,500,000 Equity Securities approved at that meeting and will not be counted towards the maximum referred to in paragraph (c):

(i) 6,319,540 Shares relating to STIs for FY26 for employees who are not Directors at an implied issue price of $0.084223.

(ii) 1,380,875 Shares relating to cash salary sacrificed by employees who are not Directors at an implied issue price of $0.137372.

(iii) 1,991,523 Shares relating to cash salary sacrificed by employees who are not Directors at an implied issue price of $0.084223.

(iv) 8,900,000 Share Rights with a term of 3 years for employees who are not Directors.

Section 200B of the Corporations Act – Background and reasons for seeking approval

The Board periodically approves a pool of long-term incentives for employees under the Incentive Plan which are subject to certain vesting hurdles. The Company's Remuneration Report sets out the Company's policies in respect to remuneration and the way in which it uses the Incentive Plan to achieve those policy objectives.

Shareholders are also being asked to approve the ability for the Board to be able to exercise certain discretions under the Incentive Plan in relation to the treatment of unvested or unexercised awards that may have been granted under the Incentive Plan.

The Corporations Act provides that the Company may only give a person a benefit in connection with their ceasing to hold a managerial or executive office in the Company or its related bodies corporate if it is approved by Shareholders or an exemption applies (for example, where the benefit together with other benefits does not exceed the base salary of the relevant person as set out in section 200F of the Corporations Act).

The term 'benefit' has a wide operation and may include (for example) the automatic or accelerated vesting of awards issued under the Incentive Plan. Under the terms of the Incentive Plan, the Board has the discretion to determine that some, or all, of those awards that have not vested or are not otherwise exercisable at the time an eligible participant ceases employment with the Company either vest, become exercisable or otherwise waive restrictions on the awards. If an eligible participant who holds, or has held, a managerial or executive office within the meaning of section 200B ceases employment with the Company, the Board may, in its discretion, determine that any awards issued to that participant which have not vested or are not otherwise exercisable will vest or become exercisable. This constitutes a 'benefit' for the purposes of section 200B of the Corporations Act.

Shareholder approval is therefore being sought, for the purposes of sections 200B and 200E of the Corporations Act, to provide benefits which may otherwise be prohibited under section 200B of the Corporations Act. If Shareholder approval is obtained, it will give the Board maximum flexibility to deal with the unvested or unexercised awards under the Incentive Plan granted to executives or key personnel who cease employment.

Shareholders are not being asked to approve any increase in the remuneration or benefits payable to relevant personnel, nor any variations to the existing discretions of the Board. Approval is sought in relation to both current and future personnel (other than Non-executive Directors) who hold or have held during the three years prior to cessation of employment a managerial or executive office in the Company or a related body corporate. Approval is not sought for the purposes of sections 200B and 200E of the Corporations Act in relation to Non-executive Directors.

The amount and value of the termination benefits for which the Company is seeking approval will depend on the discretions exercised by the Board in determining the most appropriate termination package for the relevant outgoing executives or key personnel. There is no obligation for the Board to exercise this discretion. Exercise of the discretion will depend on factors such as the participant's performance, contribution and tenure.

The amount and value of any consequent termination benefits that may be received as a result of early exercise of the awards upon cessation of employment cannot be ascertained in advance. This is because various matters, events and circumstances will or are likely to affect the calculation of the amount and value, including:

(a) the circumstances of the participant's cessation of employment (for example, whether cessation of employment arises due to resignation, retirement or redundancy);

(b) the terms contained within the invitation to participate (such as the applicable vesting conditions);

For personal use only

(c) the number of unvested or unexercised awards held by the relevant eligible participant prior to cessation of employment;

(d) the market price of the Company's shares on the ASX at the relevant time; and

(e) any other factors that the Board determines to be relevant when exercising its discretion under the Incentive Plan.

It can be reasonably anticipated that aspects of the Incentive Plan may be amended from time to time in line with market practice and changing governance standards. Where relevant, these changes will be reported in the Company's Remuneration Report. However, it is intended that this approval will remain valid for Board discretions exercised under the Incentive Plan, provided that at the time the discretion is exercised the Incentive Plan rules contain a discretion for the Board to vest all or a pro rata portion of a participant's unvested awards or to allow them to continue on foot on the terms of the Incentive Plan rules.

In all cases the number of securities (Shares, performance rights or options) that could vest upon an eligible participant ceasing employment, where the Board determines to permit an award to vest, will not exceed the maximum number of underlying Shares held by that participant.

Board recommendation: Noting that each Director is eligible to participate in the Incentive Plan, the Directors recommend that Shareholders vote FOR the Resolution in Item 5.

Item 6 – Non-executive Director Fees

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain directors of the highest calibre, whilst incurring a cost that is acceptable to Shareholders.

The Non-executive Directors are paid fixed fees in accordance with a determination of the Board but within an aggregate limit fixed by the Shareholders. Rule 8.5(a) of the Constitution and ASX Listing Rule 10.17 require the aggregate remuneration of Non-executive Directors to be determined by the Company in general meeting. The current maximum aggregate amount of $450,000 was disclosed in the Company's replacement prospectus dated 28 July 2023 and has not been increased since the Company was admitted to the official list of ASX.

The Board proposes an increase in the total aggregate remuneration of Non-executive Directors of $200,000, to $650,000 per financial year. The reasons for this change are:

- to allow the Company to attract and retain directors with the skills and experience the Company needs as the Board transitions to a majority of independent non-executive directors, including directors based outside Australia;
- the fees of several non-executive directors are set in foreign currencies, so movements in exchange rates affect the Australian dollar cost of those fees; and
- the increased cap allows for the appointment of an additional non-executive director as part of the Board's succession planning, while continuing to maintain a fee buffer to provide flexibility.

Non-executive Director cash fees currently total approximately $214,285 per annum on an annualised basis, all of which counts towards the cap. In addition, Non-executive Directors receive an equity-based component, currently totalling approximately $350,000 per annum, which is provided in Shares to preserve the Company's cash reserves. Securities issued to Non-executive Directors with Shareholder approval under the Listing Rules do not count towards the cap. However, the 4,000,000 share rights agreed to be issued to Mr Pryor, have a total value of approximately $92,000 vesting over three years, and were issued before his appointment and without Shareholder approval. They therefore count towards the fee cap. Fees paid in the financial year ending 30 June 2027 also include a one-off payment of approximately $109,254 to a former Non-executive Director in settlement of accrued equity-based remuneration.

The proposed new maximum amount leaves a reserve above current fees. The Board considers that maintaining a fee reserve will provide flexibility in planning its overall structure in advance of any specific needs arising. This may include appointing new directors to the Board prior to the resignation of current directors to facilitate an orderly succession. The increased cap is a ceiling and does not mean the full amount will be paid.

If the resolution in Item 6 is passed, the maximum total aggregate remuneration payable to Non-executive Directors will increase from $450,000 to $650,000 per financial year, with effect from the date of the Meeting. This will give the Board the flexibility to appoint additional Non-executive Directors as part of its succession planning, and to absorb the effect of exchange rate movements on fees set in foreign currencies, without exceeding the cap.

If the resolution in Item 6 is not passed, the maximum total aggregate remuneration payable to Non-executive Directors will remain at $450,000 per financial year and all payments to Non-executive Directors will continue to be made within the existing cap. This may limit the Board's ability to appoint additional Non-executive Directors or to absorb exchange rate movements, and the Board may need to review the composition of the Board or the fees paid to Non-executive Directors.

For personal use only

The following securities have been issued to Non-executive Directors under Listing Rule 10.14 with the approval of Shareholders obtained at the Company's annual general meeting held on 22 November 2023:

(a) Mr Robert Lilley: 72,917 Share Rights issued on 13 February 2024 in respect of the financial year ended 30 June 2024, and 255,672 Share Rights issued on 13 December 2024 in respect of the financial year ended 30 June 2025;

(b) Mr Hashan De Silva (a former Non-executive Director): 109,375 zero exercise price options issued on 13 February 2024 in respect of the financial year ended 30 June 2024, and 383,508 zero exercise price options issued on 13 December 2024 in respect of the financial year ended 30 June 2025; and

(c) Ms Kate Robb (a former Non-executive Director): 109,375 zero exercise price options issued on 13 February 2024 in respect of the financial year ended 30 June 2024, and 383,508 zero exercise price options issued on 13 December 2024 in respect of the financial year ended 30 June 2025.

No other securities have been issued to Non-executive Directors under Listing Rule 10.11 or 10.14 with the approval of Shareholders within the preceding three years. The Company is also seeking approval under Item 7 for the issue of Director Shares to Mr Lilley and Mr Fisher.

Board recommendation
Noting that each Non-executive Director has a personal interest in the outcome of this resolution, the Directors recommend that Shareholders vote FOR the resolution in Item 6.

Item 7 – Issues of Shares to Directors

Background

The Company proposes to issue a total of 1,542,275 Shares to three Directors (**Director Shares**), as follows:

(a) **Item 7.1**: 593,662 Shares to Mr Robert Lilley, Chair and independent Non-executive Director, as the equity-based component of his remuneration for the financial year ended 30 June 2026 (FY2026), having a value of $50,000;

(b) **Item 7.2**: 400,069 Shares to Mr Patrick Fisher, independent Non-executive Director, as the equity-based component of his remuneration for FY2026, being US$80,000 per annum pro-rated from his appointment on 19 March 2026, equivalent to $33,695 at an exchange rate of $0.67 (being the average rate for that period); and

(c) **Item 7.3**: 548,544 Shares to Dr Yu Peng, Executive Director and Chief Technology Officer (AI), in satisfaction of his short-term incentive **(STI**) for FY2026 of $46,200.

The number of Director Shares to be issued to each Director has been calculated by dividing the relevant dollar amount by $0.084223, being the volume weighted average price of Shares over the full FY2026 financial year, rounded to the nearest whole Share. Based on the closing price of Shares on ASX of $0.023 on 16 October 2026, the Director Shares have a total market value of approximately $35,472.

The equity-based component of each Non-executive Director's remuneration is provided in addition to, and not in lieu of, their cash fees. Providing this component in Shares allows the Company to preserve its cash reserves and aligns the interests of the Directors with those of Shareholders.

The Director Shares will be fully paid ordinary shares ranking equally with existing Shares and will not be subject to any vesting conditions or disposal restrictions. The Director Shares will not be issued under the Incentive Plan and will not count towards the maximum number of Equity Securities that may be issued under the Incentive Plan.

Dr Peng's FY2026 STI

Having been appointed as a Director and KMP after the close of FY2026, Dr Peng was not disclosed as KMP in the Company's 2026 Remuneration Report, so his FY2026 STI outcome is set out below. Dr Peng's maximum STI opportunity for FY2026 was 30% of his base salary of $280,000, being $84,000. The Board assessed his performance against the following KPIs:

(a) WEGO agreement, NMPA lodgement and sales (weighting 20%): 75% achieved, contributing 15%;

(b) BMD SaaS clearance and sales (weighting 50%): 50% achieved, contributing 25%;

(c) cloud-based DMP software, clearance and sales (weighting 20%): 50% achieved, contributing 10%; and

(d) Autometrics software clearance (weighting 10%): 50% achieved, contributing 5%.

Dr Peng therefore achieved 55% of his maximum STI opportunity, being $46,200. The Board has determined that, subject to Shareholder approval, the STI will be satisfied by the issue of Shares.

For personal use only

ASX Listing Rule 10.11

Listing Rule 10.11 provides that, unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to a related party without the approval of its shareholders. Each of Mr Lilley, Mr Fisher and Dr Peng is a Director and therefore a related party of the Company under Listing Rule 10.11.1. The proposed issues do not fall within any of the exceptions in Listing Rule 10.12 and therefore require Shareholder approval under Listing Rule 10.11.

If Shareholder approval is obtained under Listing Rule 10.11, approval is not required under Listing Rule 7.1 (exception 14 of Listing Rule 7.2). Accordingly, the issue of the Director Shares will not use any of the Company's 15% placement capacity under Listing Rule 7.1. Director Shares issued to Non-executive Directors with Shareholder approval will also not count towards the maximum aggregate remuneration payable to Non-executive Directors under Listing Rule 10.17 and rule 8.5 of the Constitution.

If a resolution in Item 7 is passed, the Company will issue the relevant Director Shares to the relevant Director (or his nominee).

If a resolution in Item 7 is not passed, the Company will not issue the relevant Director Shares and the Board will consider alternative arrangements to remunerate the relevant Director, which may include a cash payment of equivalent value.

Items 7.1, 7.2 and 7.3 are separate resolutions and are not contingent on the passing of any other resolution.

Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act prohibits a public company from giving a financial benefit to a related party unless shareholder approval is obtained or an exception applies. The issue of the Director Shares is the giving of a financial benefit to a related party. The Board (with each Director not participating in respect of the issue to him) considers that the issue of the Director Shares constitutes reasonable remuneration having regard to the circumstances of the Company and the responsibilities of each Director. Accordingly, the exception in section 211 of the Corporations Act applies and Shareholder approval is not being sought under section 208 of the Corporations Act.

Specific information required by Listing Rule 10.13

(a) **Names of the persons**: Mr Robert Lilley, Mr Patrick Fisher and Dr Yu Peng (or their respective nominees).

(b) **Category**: each of Mr Lilley, Mr Fisher and Dr Peng is a Director and falls within Listing Rule 10.11.1. Any nominee would be an associate of the relevant Director and fall within Listing Rule 10.11.4 or, if not an associate, would fall within Listing Rule 10.11.5.

(c) **Number and class**: 593,662 Shares to Mr Lilley, 400,069 Shares to Mr Fisher and 548,544 Shares to Dr Peng, being 1,542,275 fully paid ordinary shares in total.

(d) **Date of issue**: the Director Shares will be issued no later than one month after the date of the Meeting.

(e) **Issue price**: the Director Shares will be issued for nil cash consideration, at a deemed issue price of $0.084223 per Share. No funds will be raised from the issue.

(f) **Purpose**: to remunerate Mr Lilley and Mr Fisher by way of the equity-based component of their FY2026 remuneration, and to satisfy Dr Peng's FY2026 STI.

(g) **Current total remuneration packages**: Mr Lilley: US$100,000 cash fees per annum (paid as £75,000 per annum through the Company's UK subsidiary, plus National Insurance) plus an equity-based component of $50,000 per annum; Mr Fisher: US$50,000 cash fees per annum plus an equity-based component of US$80,000 per annum; Dr Peng: base salary of $280,000 per annum plus superannuation, plus a maximum STI opportunity of 30% of base salary.

(h) **Agreement:** The Director Shares are not being issued under an agreement.

(i) V**oting exclusion**: a voting exclusion statement is set out in the section of the Notice titled "Voting Exclusions".

Board recommendation
The Board (with Mr Lilley abstaining) recommends that Shareholders vote FOR the resolution in Item 7.1.
The Board (with Mr Fisher abstaining) recommends that Shareholders vote FOR the resolution in Item 7.2.
The Board (with Dr Peng abstaining) recommends that Shareholders vote FOR the resolution in Item 7.3.

For personal use only

Item 8 – Approval of additional 10% capacity to issue Equity Securities under ASX Listing Rule 7.1A

Background

Listing Rule 7.1A permits eligible entities to seek shareholder approval by special resolution at an annual general meeting to issue an additional 10% of its issued capital by way of placements over a 12-month period after the Annual General Meeting (**10% Placement Capacity**). The additional 10% Placement Capacity is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

If Shareholders approve the resolution in Item 8, the effect will be to allow the Company to determine to issue Equity Securities under Listing Rule 7.1A during the period of 12 months following the Meeting without using the Company's 15% placement capacity under Listing Rule 7.1. The Company could also determine to issue Equity Securities up to a combined 25% limit under Listing Rules 7.1 and 7.1A without any further shareholder approval. An approval under Listing Rule 7.1A is permissive, and not obligatory. Accordingly, if approved, the Company may or may not use the 10% Placement Capacity as the Board determines having regard to the Company's circumstances in the 12-month period following the Meeting.

Item 8 is a special resolution and therefore requires approval of at least 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

Eligibility

An eligible entity under Listing Rule 7.1A is one which (at the date of the relevant annual general meeting) has a market capitalisation of $300 million or less and is not included in the S&P / ASX 300 Index. The Company is an eligible entity for the purposes of Listing Rule 7.1A.

The Company hereby seeks Shareholder approval by way of special resolution to have the ability to issue equity securities under the 10% Placement Capacity.

The exact number of equity securities that may be issued pursuant to the 10% Placement Capacity will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 which provides that eligible entities which have obtained shareholder approval at an annual general meeting may issue or agree to issue, during the 12-month period after the date of the annual general meeting, a number of equity securities calculated as follows:

(A x D) – E

Where:

A is the number of fully paid ordinary securities on issue 12 months before the date of issue or agreement:

- plus the number of fully paid ordinary securities issued in the 12 months under an exception in Listing Rule 7.2 (other than exception 9, 16 or 17);
- plus the number of fully paid ordinary securities issued in the 12 months on the conversion of convertible securities (including convertible notes and options) within Listing Rule 7.2 exception 9 where:
    - the convertible securities were issued or agreed to be issued before the 12-month period; or
    - the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4;
- plus the number of fully paid ordinary securities issued in the 12 months under an agreement within Listing Rule 7.2 exception 16 where:
    - the agreement was entered into before the commencement of the 12-month period; or
    - the agreement or issue was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or Listing Rule 7.4;
- plus the number of partly paid ordinary securities that became fully paid in the 12 months;
- plus the number of fully paid ordinary securities issued in the 12 months with approval of shareholders under Listing Rules 7.1 or 7.4. This does not include an issue of fully paid shares under the Company's 15% placement capacity without shareholder approval. This may include fully paid ordinary securities issued in the 12-month period under an agreement to issue securities within Listing Rule 7.2 exception 17 where the issue is subsequently approved under Listing Rule 7.1;
- less the number of fully paid ordinary securities cancelled in the 12 months.

Note that **A** has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity.

D is 10%.

For personal use only

E is the number of Equity Securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that has not subsequently been approved by the holders of ordinary securities under Listing Rule 7.4.

Any equity securities issued under the 10% Placement Capacity must be in an existing quoted class of the Company's equity securities. The Company presently has one class of quoted securities, being Shares (ASX code: CVB).

If the Company issues any Equity Securities under the 10% Placement Capacity, the Company must, pursuant to Listing Rule 7.1A.4:

(a) give to the ASX immediately after the issue a list of the names of persons to whom the Company issued equity securities and the number of equity securities issued to each (but this list is not required to be released to the market); and

(b) state in an announcement of the proposed issue under Listing Rule 3.10.3 or in its application for quotation of the securities under Listing Rule 2.7 that the securities are being issued under Listing Rule 7.1A.

Required information

The following additional information is provided to Shareholders to allow them to assess the resolution in Item 8, including for the purposes of Listing Rule 7.3A.

Minimum price

Any equity securities issued by the Company under Listing Rule 7.1A can only be issued for cash consideration per security and at a price that is no less than 75% of the volume weighted average market price for securities in that class calculated over the 15 trading days on which trades in that class were recorded immediately before:

(a) the date on which the price at which the securities are to be issued is agreed by the Company and the recipient of the securities; or

(b) the date on which the securities are issued if the securities are not issued within ten trading days of the date on which the issue price is agreed.

Dilution to existing Shareholders

If the resolution in Item 8 is approved by Shareholders and the Company issues securities under the 10% Placement Capacity, the existing Shareholders' economic and voting interests in the Company will be diluted. There is a risk that the market price of the Company's securities may be significantly lower on the issue date than on the date of the Meeting and the securities may be issued at a price that is at a discount to the market price on the issue date.

The table below shows a number of hypothetical scenarios for a 10% placement as required by Listing Rule 7.3A.4 where the number of the Company's shares on issue (variable "A" in the formula in Listing Rule 7.1A.2) has remained current or increased by either 50% or 100% and the share price has decreased by 50%, remained current or increased by 100% based on the closing share price on ASX at 12 October 2026.

Variable "A" as at 12 October 2026	**Additional 10% Dilution - Shares issued & funds raised**	**Dilution**		
		$0.01 **Issue price at half current market price**	**$0.02** **Issue price at current market price**	**$0.04** **Issue price at double current market price**
734,925,708 Current Variable A **(see below assumptions)**	Shares issued (10% dilution)	73,492,570	73,492,570	73,492,570
	Funds raised	$734,925.70	$1,469,851.40	$2,939,702.80
1,102,388,562 50% increase in current Variable A	Shares issued (10% dilution)	110,238,856	110,238,856	110,238,856
	Funds raised	$1,102,388.56	$2,204,777.12	$4,409,554.24
1,469,851,416 100% increase in current Variable A	Shares issued (10% dilution)	146,985,141	146,985,141	146,985,141
	Funds raised	$1,469,851.41	$2,939,702.82	$5,879,405.64

For personal use only

The dilution table uses the following assumptions (which the Company does not represent will necessarily occur):

(a) the "issue price at current market price" is the closing price of the shares on ASX on 12 October 2026;

(b) Variable A is 734,925,708, calculated in accordance with Listing Rule 7.1A.2 as at 12 October 2026, and does not assume that the resolutions in Items 4.1, 4.2 and 4.3 are passed (if they are passed, variable A would increase to 867,125,916);

(c) the Company issues the maximum number of securities available under the additional 10% placement;

(d) the table shows only the effect of issues of securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1;

(e) no options are exercised into shares, or share rights vest, before the date of issue of equity securities;

(f) the 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%;

(g) the table does not show an example of dilution that may be caused to a particular Shareholder by reason of the placements under Listing Rule 7.1A, based on that Shareholder's holding at the date of the AGM; and

(h) funds raised are before any capital raising costs which may be incurred.

10% placement period

Shareholder approval under Listing Rule 7.1A is valid from the date of the AGM until the earlier of:

(a) 12 months after the AGM;

(b) the time and date of the Company's next annual general meeting; or

(c) the time and date of approval by Shareholders of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking).

Purpose of 10% additional placement

The Company may seek to issue securities under the 10% Placement Capacity for the purpose of raising funds for continued investment in the Company's product development, capital and financial management activities deemed by the Board to be in the best interests of the Company, and working capital requirements.

Allocation policy

The Company's allocation policy is dependent upon the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Capacity. The identity of allottees of Equity Securities will be determined on a case-by-case basis having regard to factors including but not limited to the following:

(a) the methods of raising funds that are then available to the Company;

(b) the effect of the issue of the equity securities on the control of the Company;

(c) the financial situation and solvency of the Company; and

(d) advice from professional and corporate advisers (if applicable).

Allottees have not been determined as at the date of this Notice of Meeting and may include existing and/or new Shareholders but cannot include any related parties or associates of a related party of the Company.

Information provided for compliance with Listing Rule 7.3A.6

The Company previously obtained Shareholder approval under Listing Rule 7.1A at its annual general meeting held on 27 November 2025 (**Previous Approval**).

During the 12-month period preceding the date of the Meeting, being on and from 30 November 2025, the Company issued 33,675,039 Shares pursuant to the Previous Approval, which represents approximately 6.8% of the total number of Equity Securities on issue in the Company on 30 November 2025, which was 492,699,465.

Further details of the issues of Equity Securities by the Company pursuant to Listing Rule 7.1A.2 during the 12-month period preceding the date of the Meeting are set out below.

Date of issue and Appendix 2A	4 September 2026. Appendix 2A lodged with ASX on 4 September 2026.
Recipients	The Shares were issued under the SPP to eligible Shareholders (**being Shareholders with** a registered address in Australia, New Zealand, the United States (accredited investors only), Singapore, Hong Kong, Germany, France (qualified investors only) or the United Kingdom as at the SPP record date of

For personal use only

	7:00pm (Australian Eastern Standard Time) on 7 July 2026) who applied for Shares under the SPP. The Company confirms that none of the recipients was a related party of the Company, a member of the Company's Key Management Personnel, a substantial holder of the Company, an adviser of the Company or an associate of any of these parties who was issued more than 1% of the issued capital of the Company.
The number and class of securities issued	33,675,039 fully paid ordinary shares ranking equally with all existing ordinary shares were issued under the Company's Listing Rule 7.1A capacity.
Issue price and discount to average market price	The issue price was $0.018 per Share raising approximately $606,151 and represented a discount of 10% to the closing price of Shares on ASX on 4 September 2026 of $0.020.
Cash Consideration and use of funds	The cash consideration received for the Shares issued under the Company's Listing Rule 7.1A mandate was approximately $606,151. As at the date of this Notice, none of those funds has been spent. They remain available to apply to sales and marketing expenses (including China market launch preparation for the HiRise™), R&D costs, supply chain costs and general working capital purposes.
The material terms of the Agreement	The Shares were issued on the terms of the Prospectus released to ASX on 4 August 2026, which can be viewed on the Company website at https://wcsecure.weblink.com.au/pdf/CVB/03117650.pdf

If Shareholder approval is not obtained

If Shareholders do not approve the resolution in Item 8, the Company will not be able to utilise the 10% Placement Capacity. The Company will remain subject to the 15% limit on issuing equity securities without shareholder approval set out in Listing Rule 7.1.

Board recommendation
The Board recommends that Shareholders vote FOR the resolution in Item 8.

For personal use only

Glossary

Term	Meaning
10% Placement Capacity	the additional capacity under Listing Rule 7.1A for the Company to issue Equity Securities of up to 10% of its issued capital by way of placements during the 12-month period after the Meeting
A$ or $	Australian dollars
Advisory Fee Shares	the 1,111,111 Shares issued to Spark Plus on 30 September 2026 in satisfaction of a corporate advisory fee of $20,000.
AEDT	Australian Eastern Daylight Time as observed in Melbourne, Australia
AGM, Annual General Meeting or Meeting	the annual general meeting of the Company convened by the Notice
Annual Report	the annual report of the Company for the financial year ended 30 June 2026
ASX	ASX Limited ACN 008 624 691
ASX Principles	ASX's Corporate Governance Principles and Recommendations (4th edition)
Auditor	BDO
Auditor's Report	the report of the Auditor in respect of the financial year ended 30 June 2026 contained in the Annual Report
BDO	BDO Audit Pty Ltd ABN 33 134 022 870
Board	the board of directors of the Company
Broker	SP Corporate Advisory Pty Ltd
Broker Options	the 5,000,000 unquoted options, each exercisable at $0.04 and expiring on 30 September 2027, issued on 9 October 2026 to participating brokers for services provided in connection with the Shortfall Offer and the Overflow Placement
Chair	the chair of the Meeting
Closely Related Party	has the meaning given in the Corporations Act
Company or CurveBeam AI	CurveBeam AI Limited ABN 32 140 706 618 (ASX code: CVB)
Constitution	the Company's constitution, adopted by Shareholders on 15 August 2022
Corporations Act	Corporations Act 2001 (Cth)
Director Shares	the 1,542,275 Shares proposed to be issued to Mr Robert Lilley, Mr Patrick Fisher and Dr Yu Peng (or their respective nominees) under the resolutions in Item 7
Directors	the current directors of the Company
Directors' Report	the report of the Directors for the financial year ended 30 June 2026 contained in the Annual Report
Entitlement Time	7:00pm AEDT on Saturday, 28 November 2026
Equity Securities	has the meaning given in the Listing Rules
Explanatory Memorandum	the Explanatory Memorandum accompanying and forming part of the Notice
Financial Report	the annual financial report for the Company, and the entities that it controlled, for the financial year ended 30 June 2026
Group	the Company and its subsidiaries
Incentive Plan	the CurveBeam AI Limited Omnibus Incentive Plan
Item	an item of business set out in the Notice, or any one of them, as the context requires
Key Management Personnel or **KMP**	mean persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company. The Remuneration Report identifies the Company's KMP for the financial year ended 30 June 2026.

For personal use only

Listing Rules	the Listing Rules of the ASX
LR 7.1 Shares	the 97,414,058 Shares issued under Listing Rule 7.1, comprising 77,244,236 Shares issued under the Shortfall Offer, 191,836 Shares issued under the SPP on 25 September 2026 and 19,977,986 Shares issued under the Overflow Placement.
LR 7.1A SPP Shares	the 33,675,039 Shares issued under the SPP on 4 September 2026 under Listing Rule 7.1A
Mandate	the mandate dated 31 August 2026 under which the Company engaged the Broker and Spark Plus to place the Shortfall Offer.
Notice, Notice of Meeting or **Notice of Annual General Meeting**	this notice of annual general meeting, including the sections of this notice titled "Important information" and "Voting procedures", the Explanatory Memorandum and the Proxy Form
Overflow Placement	the placement of Shares at $0.018 per Share, raising $359,603.75, made to satisfy demand under the Shortfall Offer in excess of the shortfall available
Plan Options	options granted under the Incentive Plan, each being an entitlement to receive a Share subject to the satisfaction of applicable conditions and payment of any applicable exercise price.
Prospectus	the prospectus issued by the Company dated 4 August 2026.
Proxy Deadline	9:00am AEDT on Saturday, 28 November 2026
Proxy Form	the proxy form accompanying the Notice
Share	a fully paid ordinary share in the capital of the Company
Share Rights	rights granted under the Incentive Plan, each being an entitlement to receive a Share subject to the satisfaction of applicable conditions.
Shortfall Offer	the offer under the Prospectus to investors other than eligible Shareholders of Shares not taken up under the SPP, at $0.018 per Share.
Share Registry	Computershare Investor Services Pty Limited
Shareholder	a holder of a Share
Spark Plus	Spark Plus Pte Ltd
SPP	the share purchase plan announced on 8 July 2026 and made under the Prospectus, under which eligible Shareholders could subscribe for Shares at $0.018 per Share.
VWAP	volume weighted average price

For personal use only

Annexure A – Summary of material terms of Incentive Plan

Term	Description
Eligibility	Eligible employees, Directors, officers or other service providers engaged by the Group, as determined by the Board.
Types of awards	The Company may grant securities or cash as incentives, subject to the terms of individual offers. The equity awards may be: • **Plan Options** are an entitlement to receive Shares subject to satisfaction of applicable conditions and payment of an applicable exercise price (if any). • **Share Rights** are an entitlement to receive Shares subject to the satisfaction of applicable conditions. • **Shares**, including Shares which are subject to dealing restrictions, vesting conditions or other restrictions or conditions.
Offers	Under the Incentive Plan, the Board may make offers at its discretion, subject to any requirements for Shareholder approval. The Board has the discretion to specify the terms and conditions on which it will offer incentives in individual offer documents.
Vesting	The Board shall have the discretion to determine whether service or performance-based conditions (or both) must be met before awards will vest, with conditions to be specified in the relevant offer document. The Board shall have the discretion to waive a vesting condition or to ensure that a participant is not advantaged or disadvantaged by matters outside of management's control that materially affect the Group's performance.
Issue Price	Unless the Board determines otherwise, no payment is required for a grant of a Share Right, Plan Option or Share allocated under the Incentive Plan.
Exercise	The Board will have the discretion to determine the exercise conditions (if any) that must be met before Plan Options and Share Rights may be exercised following vesting. Participants may elect to exercise their vested Plan Options or Share Rights via an exercise notice. Participants must pay an exercise price (if any) in order to exercise their vested Plan Options if required by the terms of the Plan Options. No amounts will be payable on exercise of Share Rights. In certain situations, the Board may, at its sole discretion, determine to settle the Share Rights or Plan Options in cash rather than Shares – with the cash payment equal to the value of the Shares that would be allocated to participants if Share Rights or Plan Options were Share-settled less any amount payable on exercise of the Share Rights or Plan Options. In relation to Plan Options (with an exercise price that is not nil), the Board may, on request from a participant, elect to "net settle" Plan Options on exercise. The Shares used to satisfy an award may be newly-issued Shares, transferred Shares or Shares allocated under an employee share trust. No employee share trust has been established as yet. Subject to any net-settling, each vested Plan Option or Share Right will entitle the participant to one Share.

For personal use only

Disposal restrictions	The Incentive Plan allows for disposal restrictions to be placed on awards or Shares allocated under the Incentive Plan. The details of each participant's disposal restrictions (if any) will be included in their invitation. Any disposal restriction period may be enforced through an employee share trust or via an ASX Holding Lock (administered by the Share Registry).
Cessation of employment	Under the Incentive Plan, the Board has a broad discretion in relation to the treatment of entitlements on cessation of employment. It is intended that individual offer documents will provide more specific information on how the entitlements will be treated if the participating employee or other participant ceases employment or engagement with the Company.
Clawback	The Incentive Plan provides the Board with clawback powers if, for example, the participant has acted fraudulently or dishonestly or there is a material financial misstatement.
Change of control	Unless the individual offer document states otherwise, on the event of a change of control, the Board may, by notice to participants, waive any vesting or exercise conditions, or determine that a vesting or exercise condition is satisfied, and the participant may notify the Company of exercise of their award, subject to the change of control event actually occurring. Under the Incentive Plan, a change of control will occur if: • a person (together with its related bodies corporate) becomes entitled to more than 50% of the Company's issued Shares; • when a takeover bid is made and a person obtains voting power (as that term is defined in the Corporations Act) of more than 50% and the takeover bid has become unconditional; • when a court has sanctioned a compromise or arrangement (other than for the purpose of, or in connection with, a scheme for the reconstruction of the Company); or • there is a sale of all or substantially all of the business and assets of the Group.
Capital reconstructions, bonus issues and pro-rata issues	The Incentive Plan includes specific provisions dealing with rights issues, bonus issues and corporate actions and other capital reconstructions. These provisions are intended to ensure that there is no material advantage or disadvantage to the participant in respect of their incentives as a result of such corporate actions. Participants are not entitled to participate in new issues of securities by the Company prior to the vesting (and exercise, if applicable) of their Share Rights or Plan Options. In the event of a bonus issue or pro-rata issue, Plan Options will be adjusted in the manner allowed or required by the Listing Rules.
Life of awards	Share Rights and Plan Options will expire on the date that is 10 years from the relevant grant date, or any other date specified in an individual offer document.
Maximum number of securities that may be issued under Incentive Plan	For the purposes of Listing Rule 7.2 (exception 13(b)) and the rules of the Incentive Plan, the maximum number of Awards (excluding Cash Awards) that may be issued under the Incentive Plan following Shareholder approval at the Meeting is 86,712,591. This replaces the maximum previously approved by Shareholders and does not include securities issued under the Incentive Plan before the Meeting.

For personal use only

CurveBeam AI
INFORMED IMAGING

ACN 140 706 618

Need assistance?

Phone:
1300 850 505 (within Australia)
+61 3 9415 5000 (outside Australia)

Online:
www.investorcentre.com/contact

YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **9:00am (AEDT) on Saturday, 28 November 2026.**

Proxy Form

For personal use only

SAMPLE ONLY

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

APPOINTMENT OF PROXY

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

PARTICIPATING IN THE MEETING

Corporate Representative
If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms".

Lodge your Proxy Form:

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is

Control Number: 189406

SRN/HIN:

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia

PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

☐ **Change of address.** If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with '**X**') should advise your broker of any changes.

Proxy Form

Please mark ☒ to indicate your directions

Step 1 Appoint a Proxy to Vote on Your Behalf

I/We being a member/s of CurveBeam AI Limited hereby appoint

☐ **the Chairman of the Meeting** **OR** _____

PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of CurveBeam AI Limited to be held as a virtual meeting on Monday, 30 November 2026 at 9:00am (AEDT) and at any adjournment or postponement of that meeting.

Chairman authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chairman of the Meeting as my/our proxy (or the Chairman becomes my/our proxy by default), I/we expressly authorise the Chairman to exercise my/our proxy on Items 2, 5, 6 and 7.1-7.3 (except where I/we have indicated a different voting intention in step 2) even though Items 2, 5, 6 and 7.1-7.3 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairman.

Important Note: If the Chairman of the Meeting is (or becomes) your proxy you can direct the Chairman to vote for or against or abstain from voting on Items 2, 5, 6 and 7.1-7.3 by marking the appropriate box in step 2.

Step 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

		For	Against	Abstain
Item 2	Remuneration Report	☐	☐	☐
Item 3.1	Re-election of Mr Robert Lilley as a Director	☐	☐	☐
Item 3.2	Election of Mr Patrick Fisher as a Director	☐	☐	☐
Item 3.3	Election of Dr Yu Peng as a Director	☐	☐	☐
Item 3.4	Election of Mr Daniel Pryor as a Director	☐	☐	☐
Item 4.1	Ratification of prior issue of Shares (Listing Rule 7.1)	☐	☐	☐
Item 4.2	Ratification of prior issue of Shares (Listing Rule 7.1A)	☐	☐	☐
Item 4.3	Ratification of prior issue of Advisory Fee Shares and Broker Options (Listing Rule 7.1)	☐	☐	☐
Item 5	Renewal of the Company's Omnibus Incentive Plan	☐	☐	☐
Item 6	Non-executive Director Fees	☐	☐	☐
Item 7.1	Issue of Shares to Mr Robert Lilley	☐	☐	☐
Item 7.2	Issue of Shares to Mr Patrick Fisher	☐	☐	☐
Item 7.3	Issue of Shares to Dr Yu Peng	☐	☐	☐
Item 8	Approval of additional 10% placement capacity to issue equity securities under ASX Listing Rule 7.1A	☐	☐	☐

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chairman of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

Step 3 Signature of Securityholder(s)

This section must be completed.

Individual or Securityholder 1	**Securityholder 2**	**Securityholder 3**	
			/ /
Sole Director & Sole Company Secretary	**Director**	**Director/Company Secretary**	**Date**

Update your communication details *(Optional)*

Mobile Number _____

Email Address _____

By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically

For personal use only

SAMPLE ONLY